Compositions for the transdermal delivery of pharmaceutical...

Details Compositions for the transdermal delivery of pharmaceutical... Compositions for the transdermal delivery of pharmaceutical...

A - Human Necessities

61

K

167/227

A61K 31/485 (2006.01) A61K 9/70 (2006.01) A61K 47/10 (2006.01) A61K 47/14 (2006.01)

Patent

CA 2002300

Compositions for the transdermal delivery of buprenorphine comprising a safe and effective amount of buprenorphine in a carrier comprising: (a) a polar solvent material selected from the group consist- ing of C3-C4 diols, C3-C6 triols, and mixtures thereof; and (b) a polar lipid material selected from the group consisting of fatty alcohol esters, fatty acid esters, and mixtures thereof; wherein said polar solvent material and said polar lipid material are present in a weight ratio of solvent material: lipid material of from about 60:40 to about 99:1. Preferably, the polar solvent material is propylene glycol, and the polar lipid material is an ester of a C8-C12 fatty alcohol or fatty acid . Particularly preferred polar lipid materials include methyl laurate and methyl caprylate. The ratio of polar solvent material to polar lipid material is preferably from about 90:10 to about 98:2.

Affiliated with

Also associated with

Rating

Compositions for the transdermal delivery of pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions for the transdermal delivery of pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions for the transdermal delivery of pharmaceutical... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1982462